Analyst Price Targets — PGNY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 6, 2026 5:01 pm | Brian Tanquilut | Jefferies | $30.00 | $17.79 | StreetInsider | Progyny (PGNY) PT Lowered to $30 at Jefferies |
| March 2, 2026 10:24 am | Jailendra Singh | Truist Financial | $28.00 | $17.69 | StreetInsider | Progyny (PGNY) PT Lowered to $28 at Truist Securities |
| January 21, 2026 12:17 pm | — | J.P. Morgan | $35.00 | $25.28 | TheFly | Progyny price target raised to $35 from $30 at BTIG |
| January 8, 2026 2:24 pm | Jailendra Singh | Truist Financial | $34.00 | $28.23 | TheFly | Progyny upgraded to Buy from Hold at Truist |
| January 8, 2026 12:44 pm | Scott Schoenhaus | KeyBanc | $32.00 | $26.80 | TheFly | Progyny price target raised to $32 from $30 at KeyBanc |
| December 8, 2025 9:16 pm | Peter Warendorf | Barclays | $29.00 | $24.70 | TheFly | Progyny initiated with an Overweight at Barclays |
| November 11, 2025 9:42 pm | — | KeyBanc | $30.00 | $23.81 | TheFly | KeyBanc upgrades Progyny to Overweight on 'emerging' catalysts |
| August 8, 2025 2:17 pm | Sarah James | Raymond James | $28.00 | $22.22 | StreetInsider | Cantor Fitzgerald Reiterates Overweight Rating on Progyny (PGNY) |
| July 17, 2025 12:42 pm | Jailendra Singh | Truist Financial | $27.00 | $23.05 | TheFly | Progyny price target raised to $27 from $24 at Truist |
| February 28, 2025 11:38 am | — | Canaccord Genuity | $23.00 | $22.53 | TheFly | Progyny price target raised to $23 from $17 at Canaccord |
Latest News for PGNY
NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announces Progyny Select, the industry's first fully insured, comprehensive supplemental fertility and family building plan. Available in the U.S., Progyny Select enables small employers to have access to fertility solutions in a fixed premium model.
On April 13, 2026, Progyny Inc (PGNY) shares rose 4.2% to a current price of $16.98. The stock has traded between $16.10 and $28.75 over the past 52 weeks, refl
Progyny (NASDAQ: PGNY - Get Free Report) and Surgery Partners (NASDAQ: SGRY - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation. Analyst Ratings This is a summary of current
Throughout 2026, in partnership with members, providers, and employers, Progyny will highlight a decade of innovation, expanded access, and industry-leading outcomes. Throughout 2026, in partnership with members, providers, and employers, Progyny will highlight a decade of innovation, expanded access, and industry-leading outcomes.
BG Medicine (OTCMKTS:BGMD - Get Free Report) and Progyny (NASDAQ: PGNY - Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings. Earnings and Valuation This table compares BG Medicine and
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PGNY.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.